Alimentiv and Satisfai Health Revolutionize IBD Trials with AI

Facebook
Pinterest
Twitter
LinkedIn

Alimentiv and Satisfai Health Join Forces to Advance IBD Clinical Trials with AI

In a groundbreaking move, Alimentiv, a leading global contract research organization (CRO), has partnered with Satisfai Health to leverage artificial intelligence (AI) in the assessment of gastrointestinal diseases. The collaboration introduces Certai, an AI-driven tool by Satisfai Health, now available for the secondary analysis of endoscopic video across all stages of IBD clinical trials, exclusively for Alimentiv’s sponsor clients.

This partnership signifies a major leap in the standardization of disease scoring and analysis, aiming to enhance data precision and improve patient outcomes in IBD clinical research. Experts highlight that Certai offers unparalleled accuracy by mimicking the analysis of leading IBD specialists, thereby enriching trial analysis with deep insights.

Jeff Smith, CEO of Alimentiv, expressed enthusiasm about the integration of digital technologies, noting the potential for advancements in digital biomarker discovery, precision medicine, and companion diagnostics. The collaboration is expected to reinforce Alimentiv’s position as an industry leader by ensuring more accurate trial analyses, cost efficiency, and faster project completion times. It is important to note, however, that Certai is not intended as a medical device for clinical decision-making or direct patient care.

The partnership between Alimentiv and Satisfai Health is set to open new pathways for drug development and personalized medicine in gastroenterology research, marking a significant milestone for the medical community.